Phase 2b vitiligo top-line results expected in mid-2025VYN202 Phase 1b psoriasis trial initiated with results anticipated ...

HC Wainwright reaffirmed their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE – Free Report) in a research report report published on Thursday morning,Benzinga reports. The firm currently has ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Full Year 2024 Results Key Financial Results Net loss: US$39.8m (loss widened by ...

Reports Q4 revenue $84.000 vs $76,000 last year. “Based on our significant progress in 2024, we are now positioned to announce two key data ...

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with ...

Psoriasis Statistics. Available at: Accessed January 2025. About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat ...

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with ...

Shares of VYNE stock opened at $2.74 on Wednesday. VYNE Therapeutics has a 1 year low of $1.57 and a 1 year high of $4.30. The firm’s fifty day simple moving average is $2.82 and its 200 day ...

Analysts' ratings for VYNE Therapeutics (NASDAQ:VYNE) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table provides a quick overview of their recent ...